Pralatrexate – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 89 min read

Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page11 sections

Article Summary

Pralatrexate is a folate analog inhibitor of dihydrofolate reductase (DHFR) exhibiting a high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylation and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient...

Key Takeaways

This article explains Mechanism of Action in simple medical language.
This article explains Indications in simple medical language.
This article explains Contraindications in simple medical language.
This article explains Dosage in simple medical language.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Educational health guideWritten for patient understanding and clinical awareness.

Reviewed content workflowUse writer and reviewer profiles for stronger trust.

Emergency safety firstUrgent warning signs are highlighted below.

Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Evidence Trust Passport

How this article is supported

79/100

Written byDr. Harun Ar Rashid, MD - Arthritis, Bones, Joints Pain, Trauma, and Internal Medicine Specialist

Medical review1 reviewer

Last reviewedNot scheduled

Next reviewNot scheduled

References1 source entry

Review statusReview schedule needed

Medical library classification Drug monograph Drugs A–Z

This passport makes the article’s review, evidence, and update signals visible. It does not guarantee that every section is complete or replace personal medical advice.

Definition

Pralatrexate is a folate analog inhibitor of dihydrofolate reductase (DHFR) exhibiting a high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylation and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylation pralatrexate, which is more readily affixed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at the highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.

Pralatrexate is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of peripheral T-cell lymphomas. Pralatrexate has been associated with a modest rate of serum enzyme elevations during therapy but has not been convincingly linked to instances of acute, clinically apparent liver injury.

Pralatrexate is a pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma. It has a role as an antineoplastic agent, an antimetabolite, and an EC 1.5.1.3 (dihydrofolate reductase) inhibitor. It is an N-acyl-L-glutamic acid, a member of pteridines, and a terminal acetylenic compound.

Pralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma. Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cell counterparts Compared to methotrexate, pralatrexate has better accumulation in cancer cells Pralatrexate is designed to have a higher affinity for the reduced folate carrier, a protein that is overexpressed in malignant cells and is upregulated by oncogenes As such, pralatrexate is thought to have a better therapeutic window compared to other antifolate analogs due to the novel target of RFC.^[rx]Pralatrexate was approved by the FDA on September 24, 2009. It is also being studied for other types of lymphoma and solid malignancy such as non-small-cell lung cancer, breast cancer, and bladder cancer.^[rx]

Mechanism of Action

The selectivity of pralatrexate for cancer cells is based upon the observation that cancer cells generally have overexpression of reduced folate carrier protein-1 (RTC-1) compared to normal somatic cells. This carrier protein allows the entrance of pralatrexate into the cell. Upon entering the cell, folypolyglutamate synthase FPGS catalyzes the polyglutamylation of pralatrexate so that it is retained inside the cell. Once inside, pralatrexate competitively inhibits dihydrofolate reductase (DHFR) and thymidylate synthase. Subsequent depletion of thymidine monophosphate (TMP) occurs so that the cancer cell is unable to synthesize DNA and RNA. As a result, the cancer cell cannot proliferate and is forced to undergo apoptosis. Pralatrexate is more effective against cells that are actively dividing.

Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules the synthesis of which depends on single carbon transfer.

This study evaluated mechanistic differences between pralatrexate, methotrexate, and pemetrexed. Inhibition of dihydrofolate reductase (DHFR) was quantified using recombinant human DHFR. Cellular uptake and folylpolyglutamate synthetase (FPGS) activity were determined using radiolabeled pralatrexate, methotrexate, and pemetrexed in NCI-H460 non-small cell lung cancer (NSCLC) cells. The tumor growth inhibition (TGI) was assessed using MV522 and NCI-H460 human NSCLC xenografts. Apparent K ( i ) values for DHFR inhibition were 45, 26, and >200 nM for pralatrexate, methotrexate, and pemetrexed, respectively. A significantly greater percentage of radiolabeled pralatrexate entered the cells and was polyglutamylatated relative to methotrexate or pemetrexed. In vivo, pralatrexate showed superior anti-tumor activity in both NSCLC models, with more effective dose-dependent TGI in the more rapidly growing NCI-H460 xenografts. Pralatrexate demonstrated a distinct mechanistic and anti-tumor activity profile relative to methotrexate and pemetrexed. Pralatrexate exhibited enhanced cellular uptake and increased polyglutamylation, which correlated with increased TGI in NSCLC xenograft models.

Indications

Treatment of relapsed or refractory peripheral T-cell lymphoma.
Treatment of peripheral T-cell lymphoma,
Pralatrexate is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of peripheral T-cell lymphomas.
Pralatrexate is approved to treat: Peripheral T-cell lymphoma in patients whose disease is refractory (does not respond to treatment) or has recurred (come back).
Pralatrexate is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on the overall response rate.
Cutaneous T Cell Lymphomas (CTCL)
Relapsed Peripheral T-Cell Lymphoma
Refractory Peripheral T-cell Lymphoma Unspecified

Use in Cancer

Pralatrexate is approved to treat:

Peripheral T-cell lymphoma in patients whose disease is refractory (does not respond to treatment) or has recurred (come back).

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that pralatrexate provides a clinical benefit in these patients.

Pralatrexate is also being studied in the treatment of other types of cancer.

Contraindications

Anemia, neutropenia, thrombocytopenia. Hematologic toxicity (e.g., thrombocytopenia, neutropenia, and anemia) has been reported with pralatrexate therapy
Renal disease, renal impairment
Hepatic disease
Oral ulceration
Tumor lysis syndrome (TLS)
Serious rash.
Geriatric.
Pregnancy.
anemia
decreased blood platelets
low levels of a type of white blood cell called neutrophils
stomatitis, is a condition with painful swelling and sores inside the mouth
abnormal liver function tests
pregnancy
a patient who is producing milk and breastfeeding
moderate to severe kidney impairment

Dosage

Strengths: 20 mg/mL

Lymphoma

Usual Adult Dose: 30 mg/m2 via intravenous push over 3 to 5 minutes once weekly for 6 weeks in 7-week cycles.
Duration: Until disease progression or unacceptable toxicity.
Patients should take low doses (1 mg to 1.25 mg) of oral folic acid daily.
Folic acid should start 10 days before the first dose of pralatrexate and continue for 30 days after the last dose.
Patients should also receive a B12 (1 mg) injection within 10 weeks before the first dose of pralatrexate and every 8 to 10 weeks thereafter.
Subsequent B12 injections may be given the same day as treatment with pralatrexate

Dose Adjustments

Management of severe or intolerable adverse reactions may require dose omission, reduction, or interruption of pralatrexate therapy.
Doses may be omitted or reduced based on patient tolerance. Omitted doses will not be made up at the end of the cycle. Once a dose reduction occurs for toxicity, do not re-escalate.

Dose Modifications for Mucositis:

A) If mucositis is grade 2 on the day of treatment, omit the dose. Upon recovery to grade 1 or less, continue the prior dose.
B) If mucositis is a recurrence of grade 2 on the day of treatment, omit the dose. Upon recovery to grade 1 or less, treatment may be resumed at 20 mg/m2.
C) If mucositis is grade 3 on the day of treatment, omit the dose. Upon recovery to grade 1 or less, treatment may be resumed at 20 mg/m2.
D) If mucositis is grade 4 on the day of treatment, therapy should be discontinued.

Dose Modifications for Hematologic Toxicities:
1) Blood count on day of treatment reveals a platelet less than 50,000/mcL:

A) If the duration of the toxicity is 1 week, omit the dose. Upon restart, continue the prior dose.
B) If the duration of the toxicity is 2 weeks, omit the dose. Upon restart, treatment may be resumed at 20 mg/m2.
C) If the duration of the toxicity is 3 weeks, therapy should be discontinued.

2) ANC is 500 to 1,000/mcL and no fever:

If the duration of the toxicity is 1 week, omit the dose. Upon restart, continue the prior dose.

3) ANC 500 to 1,000/mcL with fever or ANC less than 500/mcL:

A) If the duration of the toxicity is 1 week, omit the dose and give G-CSF or GM-CSF support. Upon restart, continue the prior dose with G-CSF or GM-CSF support.
B) If the duration of the toxicity is 2 weeks or a recurrence, omit the dose and give G-CSF or GM-CSF support. Upon restart, treatment may be resumed at 20 mg/m2 with G-CSF or GM-CSF support.
C) If the duration of the toxicity is 3 weeks or a second recurrence, therapy should be discontinued.

4) Dose modifications for all other treatment-related toxicities:

A) If the toxicity is grade 3, omit the dose. Upon restart, treatment may be resumed at 20 mg/m2.
B) If toxicity is grade 4, therapy should be discontinued.

Administration advice:
Prior to administering any dose of pralatrexate:

1) Mucositis should be grade 1 or less.
2) The platelet count should be greater than or equal to 100,000/mcL for the first dose and greater than or equal to 50,000/mcL for all subsequent doses.
3) The absolute neutrophil count (ANC) should be greater than or equal to 1,000/mcL.

Side Effects

The Most Common

nausea
vomiting
diarrhea
constipation
decreased appetite
tiredness
weakness
rash
itching
night sweats
stomach, back, arm, or leg pain
swelling of the hands, feet, ankles, or lower legs
white patches or sores on the lips or in the mouth and throat
fever, sore throat, cough, chills, or other signs of infection
unusual bleeding or bruising
bleeding gums
nosebleeds
small red or purple dots on the skin
blood in the urine or stool
shortness of breath
chest pain
fast or irregular heartbeat
pale skin
cold hands and feet
extreme thirst
dry, sticky mouth
sunken eyes
decreased urination
dizziness or lightheadedness

More common

Black, tarry stools
bleeding gums
blood in the urine or stools
body aches or pain
chills
convulsions
cough
cracked lips
decreased urine
diarrhea
difficult or labored breathing
difficulty with swallowing
dry mouth
ear congestion
fast, pounding, or irregular heartbeat or pulse
fever
headache
increased thirst
loss of appetite
loss of voice
lower back or side pain
mood changes
muscle pain or cramps
nasal congestion
nausea or vomiting
numbness or tingling in the hands, feet, or lips
painful or difficult urination
pale skin
pinpoint red spots on the skin
runny nose
shortness of breath
sneezing
sore throat
sores, ulcers, or white spots on the lips, tongue, or inside the mouth
swelling
tightness in the chest
troubled breathing with exertion
unusual bleeding or bruising
unusual tiredness or weakness
Abdominal or stomach pain
back pain
bloody nose
constipation
itching skin
lack or loss of strength
night sweats
pain in the arms or legs
rash
weight loss

Drug Interactions

DRUG	INTERACTION
Abacavir	Abacavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Abatacept	The risk or severity of adverse effects can be increased when Abatacept is combined with Pralatrexate.
Abemaciclib	Abemaciclib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Aceclofenac	Aceclofenac may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Acetaminophen	Acetaminophen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Acetazolamide	The therapeutic efficacy of Pralatrexate can be increased when used in combination with Acetazolamide.
Acetylsalicylic acid	The serum concentration of Pralatrexate can be increased when it is combined with Acetylsalicylic acid.
Aclidinium	Pralatrexate may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine	Pralatrexate may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir	Acyclovir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Pralatrexate.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Adenovirus	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Pralatrexate.
Afatinib	Afatinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Albutrepenonacog	Pralatrexate may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac	Alclofenac may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pralatrexate.
Alectinib	Alectinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Pralatrexate.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pralatrexate.
Allogeneic	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Pralatrexate.
Allopurinol	Allopurinol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Almasilate	Pralatrexate may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan	Almotriptan may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Alogliptin	Alogliptin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Alprazolam	Alprazolam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Pralatrexate.
Amantadine	Amantadine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Amikacin	Pralatrexate may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride	Amiloride may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Aminophenazone	Aminophenazone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Aminosalicylic acid	The serum concentration of Pralatrexate can be increased when it is combined with Aminosalicylic acid.
Amitriptyline	Amitriptyline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ammonium c	Ammonium chloride may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Amoxicillin	Amoxicillin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Amphetamine	Amphetamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Amphotericin B	Amphotericin B may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ampicillin	Ampicillin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Amrinone	Amrinone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Pralatrexate.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Pralatrexate.
Ancestim	Pralatrexate may decrease the excretion rate of Ancestim which could result in a higher serum level.
Anifrolumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Anifrolumab.
Anthrax immune	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pralatrexate.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Pralatrexate.
Antihemophilic	Pralatrexate may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antilymphocyte	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Antilymphocyte immunoglobulin (horse).
Antipyrine	Antipyrine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Antithrombin	Pralatrexate may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antithymocyte	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pralatrexate.
Antrafenine	Antrafenine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Apalutamide	Apalutamide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Pralatrexate.
Arformoterol	Arformoterol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pralatrexate.
Articaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Articaine.
COVID-19 Vacci	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Pralatrexate.
Atazanavir	Atazanavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Atomoxetine	Atomoxetine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Auranofin	Auranofin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Aurothioglucose	Pralatrexate may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Avanafil	Avanafil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Avatrombopag	Avatrombopag may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Pralatrexate.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Pralatrexate.
Azelaic acid	Azelaic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Aztreonam	Aztreonam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Bacillus calmett	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Pralatrexate.
Bacillus liv antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Pralatrexate.
Bacillus antigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Pralatrexate.
Bacitracin	Bacitracin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Baclofen	Baclofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Balsalazide	The serum concentration of Pralatrexate can be increased when it is combined with Balsalazide.
Baricitinib	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Pralatrexate.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Pralatrexate.
Beclomethasone	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pralatrexate.
Belatacept	The risk or severity of adverse effects can be increased when Belatacept is combined with Pralatrexate.
Belimumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Belinostat is combined with Pralatrexate.
Belumosudil	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Belumosudil.
Bendamustine	The risk or severity of adverse effects can be increased when Bendamustine is combined with Pralatrexate.
Bendroflumethia	Bendroflumethiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Benorilate	Benorilate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Benoxaprofen	Benoxaprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Benserazide	Pralatrexate may decrease the excretion rate of Benserazide which could result in a higher serum level.
Benzatropine	Benzatropine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Benznidazole	Pralatrexate may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Benzocaine.
Benzthiazide	Benzthiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Benzydamine	Benzydamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Benzyl alcohol.
Bepotastine	Bepotastine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Pralatrexate.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Pralatrexate.
Bicisate	Pralatrexate may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bimekizumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Bimekizumab.
Bismuth subgallate	Pralatrexate may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bismuth subsalicylate	The serum concentration of Pralatrexate can be increased when it is combined with Bismuth subsalicylate.

Bisoprolol	Bisoprolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Bisoxatin	Pralatrexate may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Pralatrexate.
Blinatumomab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Blinatumomab.
Bordetella pertussis	The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Pralatrexate.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Pralatrexate.
Bosutinib	The risk or severity of adverse effects can be increased when Bosutinib is combined with Pralatrexate.
Brentuximab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Brentuximab vedotin.
Brigatinib	Brigatinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Brivaracetam	Brivaracetam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Brodalumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Brodalumab.
Bromazepam	Bromazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Bromotheophylline	Bromotheophylline may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Budesonide	The risk or severity of adverse effects can be increased when Budesonide is combined with Pralatrexate.
Bumadizone	Bumadizone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Bumetanide	Bumetanide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Bupivacaine.
Buprenorphine	Buprenorphine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Bupropion	Bupropion may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Buspirone	Buspirone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Pralatrexate.
Butabarbital	Butabarbital may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Butacaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Butamben.
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pralatrexate.
Caffeine	Caffeine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Canagliflozin	Canagliflozin may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Canakinumab	The risk or severity of adverse effects can be increased when Canakinumab is combined with Pralatrexate.
Cannabidiol	Cannabidiol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Canrenoic acid	Canrenoic acid may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Capecitabine	The risk or severity of adverse effects can be increased when Capecitabine is combined with Pralatrexate.
Capmatinib	The serum concentration of Pralatrexate can be increased when it is combined with Capmatinib.
Capreomycin	Pralatrexate may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Capsaicin.
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Pralatrexate.
Carbidopa	Carbidopa may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Pralatrexate.
Carfilzomib	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Carfilzomib.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Pralatrexate.
Carprofen	Carprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefaclor	Cefaclor may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefadroxil	Cefadroxil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefalotin	Cefalotin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefamandole	Cefamandole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefapirin	Cefapirin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefazolin	Cefazolin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefdinir	Cefdinir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefditoren	Cefditoren may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefepime	Cefepime may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefmenoxime	Cefmenoxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefmetazole	Cefmetazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefonicid	Cefonicid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefoperazone	Cefoperazone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ceforanide	Ceforanide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefotaxime	Cefotaxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefotetan	Cefotetan may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefotiam	Cefotiam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefoxitin	Cefoxitin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefpiramide	Cefpiramide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefpirome	Cefpirome may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefpodoxime	Cefpodoxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefprozil	Cefprozil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefradine	Cefradine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ceftaroline	Ceftaroline fosamil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ceftazidime	Ceftazidime may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ceftibuten	Ceftibuten may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ceftizoxime	Ceftizoxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ceftobiprole	Ceftobiprole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ceftolozane	Pralatrexate may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone	Ceftriaxone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cefuroxime	Cefuroxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Celecoxib	Celecoxib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cephalexin	Cephalexin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cephaloglycin	Cephaloglycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Certolizumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Certolizumab pegol.
Cetirizine	Cetirizine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cevimeline	Cevimeline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Chloral hydrate	Chloral hydrate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Pralatrexate.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Pralatrexate.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Chloroprocaine.
Chloroquine	Chloroquine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Chlorothiazide	Chlorothiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Chloroxylenol	Pralatrexate may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
Chlorpromazine	Chlorpromazine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Chlorpropamide	Chlorpropamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Chlorthalidone	Chlorthalidone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Chlorzoxazone	Chlorzoxazone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cholesterol	Cholesterol may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Choline C 11	Pralatrexate may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
Choline magnesium	Choline magnesium trisalicylate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Choline salicylate	The serum concentration of Pralatrexate can be increased when it is combined with Choline salicylate.
Chondroitin sulfate	Pralatrexate may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride	Pralatrexate may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromic nitrate	Pralatrexate may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium	Pralatrexate may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium gluconate	Pralatrexate may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicotinate	Pralatrexate may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate	Pralatrexate may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Ciclesonide	The risk or severity of adverse effects can be increased when Ciclesonide is combined with Pralatrexate.

Cidofovir	Cidofovir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cilostazol	Cilostazol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cimetidine	Cimetidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Cinchocaine.
Ciprofloxacin	Ciprofloxacin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Pralatrexate.
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Pralatrexate.
Clevidipine	Clevidipine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Clobazam	Clobazam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Clobetasol	The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Pralatrexate.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Pralatrexate.
Clofazimine	Clofazimine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Clomipramine	Clomipramine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Clonazepam	Clonazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Clorazepic acid	Clorazepic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Clostridium	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pralatrexate.
Clove oil	Pralatrexate may decrease the excretion rate of Clove oil which could result in a higher serum level.
Clozapine	Clozapine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cobicistat	Cobicistat may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cocaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Cocaine.
Colchicine	Colchicine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Colistimethate	Colistimethate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Colistin	Pralatrexate may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan	Conivaptan may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
C estrogens	Conjugated estrogens may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Corifollitropin alfa	Pralatrexate may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
Corticotropin	The risk or severity of adverse effects can be increased when Corticotropin is combined with Pralatrexate.
Cortisone acetate	The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Pralatrexate.
Corynebacterium	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pralatrexate.
Cyanocobalamin	Cyanocobalamin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Cyclopenthiazide	Cyclopenthiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pralatrexate.
Cyclosporine	Pralatrexate may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	Cyclothiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Pralatrexate.
Dabigatran	Dabigatran etexilate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dabrafenib	Dabrafenib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Pralatrexate.
Daclatasvir	Daclatasvir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dacomitinib	Dacomitinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Pralatrexate.
Dalfampridine	Dalfampridine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dapagliflozin	Dapagliflozin may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Daptomycin	Daptomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pralatrexate.
Darolutamide	Darolutamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dasabuvir	Dasabuvir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dasatinib	The risk or severity of adverse effects can be increased when Dasatinib is combined with Pralatrexate.
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pralatrexate.
Decitabine	The risk or severity of adverse effects can be increased when Decitabine is combined with Pralatrexate.
Deferiprone	Pralatrexate may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Deflazacort	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Deflazacort.
Delafloxacin	Pralatrexate may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Pralatrexate.
Desipramine	Desipramine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Desmopressin	Desmopressin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Desoximetasone	The risk or severity of adverse effects can be increased when Desoximetasone is combined with Pralatrexate.
Desvenlafaxine	Desvenlafaxine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Deucravacitinib	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Deucravacitinib.
Deutetrabenazine	Pralatrexate may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Dexamethasone	The risk or severity of adverse effects can be increased when Dexamethasone is combined with Pralatrexate.
Dexamethasone	Dexamethasone acetate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dexibuprofen	Dexibuprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dexketoprofen	Dexketoprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dexmedetomidine	Dexmedetomidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dexpanthenol	Pralatrexate may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pralatrexate.
Dextran	Pralatrexate may decrease the excretion rate of Dextran which could result in a higher serum level.
Diatrizoate	Diatrizoate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Diazepam	Diazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dichlorobenzyl	Pralatrexate may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Diclofenac	Diclofenac may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Diclofenamide	Diclofenamide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Dicyclomine	Dicyclomine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Didanosine	Didanosine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dienogest	Pralatrexate may decrease the excretion rate of Dienogest which could result in a higher serum level.
Diethylstilbestrol	Diethylstilbestrol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Diflunisal	The serum concentration of Pralatrexate can be increased when it is combined with Diflunisal.
Difluocortolone	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Difluocortolone.
Digoxin	Pralatrexate may decrease the excretion rate of Digoxin which could result in a higher serum level.
Dihydrostreptomycin	Dihydrostreptomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dimercaprol	Dimercaprol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Dimethyl fumarate.
Dimethyl sulfoxide	Dimethyl sulfoxide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Dinutuximab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Dinutuximab.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Diphenhydramine.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Diroximel fumarate.
Disopyramide	Disopyramide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
DL-Methylephedrine	Pralatrexate may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Dobutamine	Dobutamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Pralatrexate.
Dopamine	Dopamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Doripenem	Doripenem may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Doxacurium	Doxacurium may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Doxepin	Doxepin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Doxorubicin	The risk or severity of adverse effects can be increased when Doxorubicin is combined with Pralatrexate.
Doxycycline	Doxycycline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Drospirenone	Drospirenone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Droxidopa	Droxidopa may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Duloxetine	Duloxetine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.

Dyclonine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Dyclonine.
Dyphylline	Dyphylline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ebola Zaire vaccine	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Pralatrexate.
Eculizumab	The risk or severity of adverse effects can be increased when Eculizumab is combined with Pralatrexate.
Edoxaban	Pralatrexate may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Edrophonium	Edrophonium may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Pralatrexate.
Elbasvir	Elbasvir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Eltrombopag	Eltrombopag may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Emapalumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Emapalumab.
Enalaprilat	Pralatrexate may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Enasidenib	Enasidenib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Enzalutamide	Pralatrexate may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Pralatrexate.
Eplerenone	Eplerenone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Epoprostenol	Epoprostenol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Eribulin	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Eribulin.
Erlotinib	Erlotinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ertapenem	Ertapenem may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ertugliflozin	Ertugliflozin may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pralatrexate.
Estazolam	Estazolam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Estradiol	Estradiol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Estradiol acetate	Estradiol acetate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Estradiol benzoate	Estradiol benzoate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Estradiol cypionate	Estradiol cypionate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Estradiol dienanthate	Estradiol dienanthate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Estradiol valerate	Estradiol valerate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Estramustine	The risk or severity of adverse effects can be increased when Estramustine is combined with Pralatrexate.
Estrone sulfate	Estrone sulfate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Eszopiclone	Eszopiclone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Etacrynic acid	Etacrynic acid may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Etafedrine	Pralatrexate may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Pralatrexate.
Ethambutol	Ethambutol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Etidocaine.
Etodolac	Etodolac may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Etomidate	Etomidate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Etonogestrel	Etonogestrel may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Pralatrexate.
Etoricoxib	Etoricoxib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Eucalyptus oil	Pralatrexate may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Everolimus	The risk or severity of adverse effects can be increased when Everolimus is combined with Pralatrexate.
Ezogabine	Ezogabine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Famtozinameran	The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Pralatrexate.
Febuxostat	The excretion of Pralatrexate can be decreased when combined with Febuxostat.
Fedratinib	Fedratinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Fenbufen	Fenbufen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Fenofibrate	Fenofibrate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Fenofibric acid	Pralatrexate may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam	Fenoldopam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Fenoprofen	Fenoprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Fentanyl	Fentanyl may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Fesoterodine	Fesoterodine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Filgotinib	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Filgotinib.
Finerenone	Finerenone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Fingolimod	Pralatrexate may increase the immunosuppressive activities of Fingolimod.
Flavoxate	Flavoxate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Floctafenine	Floctafenine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Florbetaben	Pralatrexate may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir	Pralatrexate may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Pralatrexate.
Fluconazole	Fluconazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Flucytosine	The risk or severity of adverse effects can be increased when Flucytosine is combined with Pralatrexate.
Fludarabine	The risk or severity of adverse effects can be increased when Fludarabine is combined with Pralatrexate.
Fludeoxyglucose	Pralatrexate may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pralatrexate.
Flumazenil	Flumazenil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Pralatrexate.
Fluocinolone	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Pralatrexate.
Fluocinonide	The risk or severity of adverse effects can be increased when Fluocinonide is combined with Pralatrexate.
Fluocortolone	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Fluocortolone.
Fluorometholone	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Pralatrexate.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pralatrexate.
Fluprednisolone	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Fluprednisolone.
Flurazepam	Flurazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Flurbiprofen	Flurbiprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Flutamide	Flutamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Fluticasone	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Fluticasone.
Fluticasone	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Fluticasone furoate.
Fluticasone	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pralatrexate.
Fluvoxamine	Fluvoxamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Folic acid	The therapeutic efficacy of Pralatrexate can be decreased when used in combination with Folic acid.
Fomepizole	Fomepizole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Fondaparinux	Fondaparinux may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Formestane	Pralatrexate may decrease the excretion rate of Formestane which could result in a higher serum level.
Foscarnet	Foscarnet may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Fosfomycin	Fosfomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Fosinopril	Fosinopril may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Fostamatinib	Fostamatinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Fostemsavir	Fostemsavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Framycetin	Framycetin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Furosemide	Furosemide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Fusidic acid	Fusidic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Gabapentin	Pralatrexate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Gadobenic acid	Gadobenic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Gadodiamide	Gadodiamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Gadofosveset	Gadofosveset trisodium may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Gadopentetic acid	Gadopentetic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.

Gadoteric acid	Pralatrexate may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol	Gadoteridol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Gallium nitrate	The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Pralatrexate.
Ganciclovir	Ganciclovir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Gefitinib	Gefitinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Pralatrexate.
Gemfibrozil	Gemfibrozil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Gemtuzumab	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pralatrexate.
Gentamicin	Pralatrexate may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gilteritinib	Gilteritinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Gimeracil	Pralatrexate may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Givosiran	Givosiran may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Glasdegib	Glasdegib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Glatiramer	The risk or severity of adverse effects can be increased when Glatiramer is combined with Pralatrexate.
Glecaprevir	Glecaprevir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Glipizide	Glipizide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Glucarpidase	The serum concentration of the active metabolites of Pralatrexate can be reduced when Pralatrexate is used in combination with Glucarpidase resulting in a loss in efficacy.
Glycerol	Pralatrexate may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Glycol salicylate	Glycol salicylate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Golimumab	The risk or severity of adverse effects can be increased when Golimumab is combined with Pralatrexate.
Golodirsen	Pralatrexate may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin	Goserelin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Grazoprevir	Grazoprevir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Guanethidine	Guanethidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Guanfacine	Guanfacine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Guselkumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Guselkumab.
Haemophilus	The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Pralatrexate.
Haloperidol	Haloperidol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Hepatitis A Vaccine	The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pralatrexate.
Hepatitis B	The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pralatrexate.
Human adenovirus	The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Pralatrexate.
Hydralazine	Hydralazine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Hydrochlorothiazide	Hydrochlorothiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Hydrocortisone	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Hydrocortisone acetate.
Hydrocortisone	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Hydrocortisone butyrate.
Hydrocortisone	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Hydrocortisone succinate.
Hydroflumethiazide	Hydroflumethiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Hydromorphone	Hydromorphone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Hydroxocobalamin	Hydroxocobalamin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Pralatrexate.
Hydroxyethyl Starch	Pralatrexate may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Pralatrexate.
Ibritumomab	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pralatrexate.
Ibrutinib	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ibrutinib.
Ibuprofen	Ibuprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ibutilide	Ibutilide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Icatibant	Icatibant may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Icosapent	Icosapent may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Idarubicin	The risk or severity of adverse effects can be increased when Idarubicin is combined with Pralatrexate.
Idarucizumab	Pralatrexate may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Idebenone	Pralatrexate may decrease the excretion rate of Idebenone which could result in a higher serum level.
Idelalisib	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Idelalisib.
Ifosfamide	The risk or severity of adverse effects can be increased when Ifosfamide is combined with Pralatrexate.
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Pralatrexate.
Imipramine	Imipramine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Indapamide	Indapamide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Indigotindisulfonic	Pralatrexate may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Indomethacin	Indomethacin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Inebilizumab	The risk or severity of infection can be increased when Pralatrexate is combined with Inebilizumab.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Pralatrexate.

Isradipine	Isradipine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Istradefylline	Istradefylline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Itraconazole	Itraconazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ixabepilone	The risk or severity of adverse effects can be increased when Ixabepilone is combined with Pralatrexate.
Ixazomib	Pralatrexate may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Ixekizumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ixekizumab.
COVID-19 Vaccine	The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Pralatrexate.
J encephalitis	The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Pralatrexate.
Kanamycin	Pralatrexate may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Ketamine	Ketamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ketazolam	Ketazolam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ketoprofen	Ketoprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ketorolac	Ketorolac may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Labetalol	Labetalol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lamivudine	Lamivudine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lamotrigine	Lamotrigine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lansoprazole	Lansoprazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lasmiditan	The serum concentration of Pralatrexate can be increased when it is combined with Lasmiditan.
Latamoxef	Latamoxef may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ledipasvir	Ledipasvir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Leflunomide	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Leflunomide.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Pralatrexate.
Lesinurad	Pralatrexate may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Letermovir	Letermovir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Leucovorin	The therapeutic efficacy of Pralatrexate can be decreased when used in combination with Leucovorin.
Leuprolide	Leuprolide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Levobupivacaine.
Levocarnitine	Levocarnitine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Levocetirizine	Levocetirizine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Levofloxacin	Levofloxacin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Levoleucovorin	The therapeutic efficacy of Pralatrexate can be decreased when used in combination with Levoleucovorin.
Levomilnacipran	Pralatrexate may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Levosalbutamol	Pralatrexate may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Lidocaine.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Pralatrexate.
Liothyronine	Liothyronine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lisinopril	Lisinopril may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lithium carbonate	Pralatrexate may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Lithium citrate	Lithium citrate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lixisenatide	Pralatrexate may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Lofexidine	Lofexidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lomustine	The risk or severity of adverse effects can be increased when Lomustine is combined with Pralatrexate.
Lopinavir	The serum concentration of Pralatrexate can be increased when it is combined with Lopinavir.
Loracarbef	Loracarbef may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lorazepam	Lorazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lorcaserin	Lorcaserin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lornoxicam	Lornoxicam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lorpiprazole	Pralatrexate may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
Loxoprofen	Loxoprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lubiprostone	Lubiprostone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Lumiracoxib	Lumiracoxib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Macitentan	Pralatrexate may decrease the excretion rate of Macitentan which could result in a higher serum level.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Pralatrexate.
Magnesium	Pralatrexate may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Magnesium chlo	Pralatrexate may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium	Pralatrexate may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium tris	Pralatrexate may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Mangafodipir	Mangafodipir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Mannitol	Mannitol may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Maprotiline	Maprotiline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Maribavir	Maribavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Measles virus	The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Pralatrexate.
Mecamylamine	Mecamylamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Pralatrexate.
Meclofenamic acid	Meclofenamic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Medroxyprogeste	Medroxyprogesterone acetate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Mefenamic acid	Mefenamic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Megestrol acetate	Megestrol acetate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Meloxicam	Meloxicam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Melphalan	The risk or severity of adverse effects can be increased when Melphalan is combined with Pralatrexate.
Memantine	Memantine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Meningococcal	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Pralatrexate.
Menthyl salicylate	Menthyl salicylate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Meperidine	Meperidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Mepolizumab is combined with Pralatrexate.
Meprednisone	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Meprednisone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Pralatrexate.
Meropenem	Meropenem may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Mesalazine	The serum concentration of Pralatrexate can be increased when it is combined with Mesalazine.
Metamfetamine	Metamfetamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Metamizole	Metamizole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Metaxalone	Metaxalone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Metformin	Metformin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Methadone	Methadone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Methazolamide	Methazolamide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Methimazole	The risk or severity of adverse effects can be increased when Methimazole is combined with Pralatrexate.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Pralatrexate.
Methoxsalen	Methoxsalen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Methoxy	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pralatrexate.
Methyl salicylate	The serum concentration of Pralatrexate can be increased when it is combined with Methyl salicylate.
Methyldopa	Methyldopa may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Methylene blue	Pralatrexate may decrease the excretion rate of Methylene blue which could result in a higher serum level.
Methylnaltrexone	Methylnaltrexone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Methylprednisolone	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pralatrexate.
Methyltestosterone	Methyltestosterone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Meticrane	Meticrane may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Metoclopramide	Metoclopramide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Metolazone	Metolazone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Metoprolol	Metoprolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.

Metyrapone	Metyrapone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Midazolam	Midazolam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Migalastat	Migalastat may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Milnacipran	Milnacipran may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Milrinone	Milrinone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Mirabegron	Pralatrexate may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Pralatrexate.
Mitoxantrone	The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Pralatrexate.
COVID-19 Vaccine	The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Pralatrexate.
accinia ankara	The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Pralatrexate.
Mometasone	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Mometasone furoate.
Monomethyl	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Monomethyl fumarate.
Mosunetuzumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Mosunetuzumab.
Moxisylyte	Pralatrexate may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Mumps virus	The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Pralatrexate.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Pralatrexate.
Muzolimine	Muzolimine may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolate	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pralatrexate.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pralatrexate.
N-acetyltyrosine	Pralatrexate may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabumetone	Nabumetone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Nadolol	Nadolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Naldemedine	Pralatrexate may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalmefene	Nalmefene may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Naloxone	Naloxone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Naproxen	Naproxen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Natalizumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Natalizumab.
Nateglinide	Nateglinide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Nedaplatin	Pralatrexate may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Nedocromil	Nedocromil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Nefazodone	Nefazodone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Nelarabine	The risk or severity of adverse effects can be increased when Nelarabine is combined with Pralatrexate.
Nelfinavir	Nelfinavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Neomycin	Pralatrexate may decrease the excretion rate of Neomycin which could result in a higher serum level.
Netilmicin	Pralatrexate may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Nicorandil	Pralatrexate may decrease the excretion rate of Nicorandil which could result in a higher serum level.
Nifedipine	Nifedipine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Nilotinib	The risk or severity of adverse effects can be increased when Nilotinib is combined with Pralatrexate.
Nilutamide	Nilutamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Nimesulide	Nimesulide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Nisoldipine	Nisoldipine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Nitric Oxide	Nitric Oxide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Nitrofurantoin	Nitrofurantoin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Nitroprusside	Nitroprusside may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Novobiocin	Novobiocin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Pralatrexate.
Obinutuzumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Obinutuzumab.
Ocrelizumab	Ocrelizumab may increase the immunosuppressive activities of Pralatrexate.
Octinoxate	Pralatrexate may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Ofatumumab	The risk or severity of adverse effects can be increased when Ofatumumab is combined with Pralatrexate.
Olaparib	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Olaparib.
Olsalazine	The serum concentration of Pralatrexate can be increased when it is combined with Olsalazine.
Omeprazole	Omeprazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Opium	Pralatrexate may decrease the excretion rate of Opium which could result in a higher serum level.
Oseltamivir	Oseltamivir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Osimertinib	Osimertinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Oteseconazole	The serum concentration of Pralatrexate can be increased when it is combined with Oteseconazole.
Oxacillin	Oxacillin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pralatrexate.
Oxaprozin	Oxaprozin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Oxazepam	Oxazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Oxetacaine.
Oxybenzone	Oxybenzone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Oxybuprocaine.
Oxyphenbutazone	Oxyphenbutazone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Oxyquinoline	Pralatrexate may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Ozanimod	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ozanimod.
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pralatrexate.
Pacritinib	The serum concentration of Pralatrexate can be increased when it is combined with Pacritinib.
Palbociclib	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Palbociclib.
Paliperidone	Paliperidone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron	Palonosetron may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pamidronic acid	Pamidronic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Panobinostat	The risk or severity of adverse effects can be increased when Panobinostat is combined with Pralatrexate.
Pantoprazole	Pantoprazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Parecoxib	Parecoxib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Paritaprevir	Paritaprevir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Paromomycin	Paromomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Patent Blue	Pralatrexate may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Pazopanib	The risk or severity of adverse effects can be increased when Pazopanib is combined with Pralatrexate.
Pegaptanib	Pegaptanib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pralatrexate.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Pralatrexate.
Peginterferon alfa	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pralatrexate.
Peginterferon alfa	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pralatrexate.
Peginterferon beta	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Peginterferon beta-1a.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Pralatrexate.
Penbutolol	Penbutolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Pralatrexate.
Pentaerythritol	Pentaerythritol tetranitrate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pentamidine	Pentamidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pentastar	Pralatrexate may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Pentetic acid	Pralatrexate may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital	Pentobarbital may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Pralatrexate.
Pentoxifylline	Pentoxifylline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Perindopril	Perindopril may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Permethrin	Permethrin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Pralatrexate.

Phenelzine	Phenelzine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Phenol	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Phenol.
Phentolamine	Phentolamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Phenyl aminosalicy	The serum concentration of Pralatrexate can be increased when it is combined with Phenyl aminosalicylate.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pralatrexate.
Phenylbutazone	Phenylbutazone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pholcodine	Pralatrexate may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Phosphoric acid	Pralatrexate may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone	Phylloquinone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pibrentasvir	Pibrentasvir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Picosulfuric acid	Pralatrexate may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pralatrexate.
Pindolol	Pindolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Piperacillin	Piperacillin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Piracetam	Pralatrexate may decrease the excretion rate of Piracetam which could result in a higher serum level.
Piretanide	Piretanide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Pralatrexate.
Piroxicam	Piroxicam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pitolisant	Pralatrexate may decrease the excretion rate of Pitolisant which could result in a higher serum level.
Plazomicin	Pralatrexate may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plerixafor	Plerixafor may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Polythiazide	Polythiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Pomalidomide	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Pomalidomide.
Ponatinib	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ponatinib.
Ponesimod	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ponesimod.
Potassium	Potassium may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate	Pralatrexate may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium	Pralatrexate may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium cation	Potassium cation may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Potassium chloride	Potassium chloride may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Potassium citrate	Potassium citrate may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Potassium nitrate	Pralatrexate may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium	Pralatrexate may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
Potassium sulfate	Pralatrexate may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Pralidoxime	Pralidoxime may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pralsetinib	Pralsetinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pramipexole	Pramipexole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Pramocaine.
Prasugrel	Prasugrel may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pravastatin	Pravastatin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Prednisolone	The risk or severity of adverse effects can be increased when Prednisolone is combined with Pralatrexate.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Pralatrexate.
Pregabalin	Pregabalin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Prilocaine.
Probenecid	The serum concentration of Pralatrexate can be increased when it is combined with Probenecid.
Procainamide	Pralatrexate may decrease the excretion rate of Procainamide which could result in a higher serum level.
Procaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Procaine.
Procaine	Pralatrexate may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Pralatrexate.
Progesterone	Progesterone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Promethazine	Promethazine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Propantheline	Propantheline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Proparacaine.
Propiverine	Pralatrexate may decrease the excretion rate of Propiverine which could result in a higher serum level.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Propoxycaine.
Propranolol	Propranolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pralatrexate.
Prucalopride	Prucalopride may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pyrantel	Pralatrexate may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide	Pyrazinamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pyridoxine	Pyridoxine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pyrithione	Pralatrexate may decrease the excretion rate of Pyrithione which could result in a higher serum level.
Quetiapine	Quetiapine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Quinethazone	Quinethazone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Quinidine	Pralatrexate may decrease the excretion rate of Quinidine which could result in a higher serum level.
Rabeprazole	Rabeprazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Rabies i	The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Pralatrexate.
Rabies antigen, A	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pralatrexate.
Rabies antigen, B	The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Pralatrexate.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Pralatrexate.
Ramelteon	Ramelteon may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ranitidine	Ranitidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ranolazine	Ranolazine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Rasagiline	Rasagiline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ravulizumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ravulizumab.
Regorafenib	Regorafenib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Reserpine	Reserpine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Resorcinol	Pralatrexate may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Ribavirin	Ribavirin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ribostamycin	Pralatrexate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
Rilonacept	The risk or severity of adverse effects can be increased when Rilonacept is combined with Pralatrexate.
Rilpivirine	Rilpivirine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ripretinib	Ripretinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Risankizumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Risankizumab.
Ritonavir	Ritonavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Pralatrexate.
Rivaroxaban	Rivaroxaban may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Rizatriptan	Rizatriptan may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Rofecoxib	Rofecoxib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Pralatrexate.
Rolapitant	Rolapitant may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ropeginterferon	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Ropivacaine.
Rosiglitazone	Rosiglitazone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Pralatrexate.
Roxadustat	The serum concentration of Pralatrexate can be increased when it is combined with Roxadustat.
Rubella virus vaccine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Pralatrexate.
Rucaparib	Rucaparib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Ruxolitinib	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ruxolitinib.

Sacubitril	Pralatrexate may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Safinamide	Safinamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Salbutamol	Salbutamol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Salicylamide	Salicylamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Salicylic acid	The serum concentration of Pralatrexate can be increased when it is combined with Salicylic acid.
Salmon calcitonin	Salmon calcitonin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Salsalate	Salsalate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Sapropterin	The serum concentration of Sapropterin can be decreased when it is combined with Pralatrexate.
Saquinavir	Saquinavir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Sarilumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Sarilumab.
Satralizumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Satralizumab.
Saxagliptin	Saxagliptin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Secobarbital	Secobarbital may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Secukinumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Secukinumab.
Selenious acid	Pralatrexate may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium	Pralatrexate may decrease the excretion rate of Selenium which could result in a higher serum level.
Sibutramine	Sibutramine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Siltuximab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Siltuximab.
Simeprevir	Simeprevir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Siponimod	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Siponimod.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pralatrexate.
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Pralatrexate.
Sitagliptin	Sitagliptin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Smallpox	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Pralatrexate.
Sodium acetate	Pralatrexate may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium	Pralatrexate may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Sodium fluoride	Pralatrexate may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium sulfate	Pralatrexate may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Sofosbuvir	Pralatrexate may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Solriamfetol	Pralatrexate may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Pralatrexate.
Sorbitol	Sorbitol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Sotagliflozin	Sotagliflozin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Sotorasib	The serum concentration of Pralatrexate can be increased when it is combined with Sotorasib.
Spesolimab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Spesolimab.
Spironolactone	Spironolactone may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Stiripentol	The excretion of Pralatrexate can be decreased when combined with Stiripentol.
Streptomycin	Pralatrexate may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Pralatrexate.
Strontium chloride	Pralatrexate may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
Sucralfate	Sucralfate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Sulbactam	Pralatrexate may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulfadiazine	Sulfadiazine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Sulfamethoxazole	Pralatrexate may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.
Sulfasalazine	The serum concentration of Pralatrexate can be increased when it is combined with Sulfasalazine.
Sulindac	Sulindac may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Sumatriptan	Sumatriptan may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Sunitinib	The risk or severity of adverse effects can be increased when Sunitinib is combined with Pralatrexate.
SEstrogens, A	Pralatrexate may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
SEstrogens, B	Pralatrexate may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Pralatrexate.
Tadalafil	Tadalafil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tafamidis	The serum concentration of Pralatrexate can be increased when it is combined with Tafamidis.
Tamsulosin	Tamsulosin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tasimelteon	Pralatrexate may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Taurocholic acid	Taurocholic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Technetium	Pralatrexate may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium	Pralatrexate may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
Technetium	Pralatrexate may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
Technetium	Pralatrexate may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Teduglutide	Pralatrexate may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Tegafur	Pralatrexate may decrease the excretion rate of Tegafur which could result in a higher serum level.
Telavancin	Telavancin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Telmisartan	Telmisartan may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Temazepam	Temazepam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Pralatrexate.
Temsirolimus	The risk or severity of adverse effects can be increased when Temsirolimus is combined with Pralatrexate.
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Pralatrexate.
Tenofovir	The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pralatrexate.
Tenofovir disoproxil	Tenofovir disoproxil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tenoxicam	Tenoxicam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tepotinib	Tepotinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Teprotumumab	The risk or severity of adverse effects can be increased when Teprotumumab is combined with Pralatrexate.
Terbutaline	Terbutaline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Teriflunomide	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Teriflunomide.
Testolactone	Testolactone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Testosterone	Testosterone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Testosterone	Pralatrexate may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone	Pralatrexate may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone	Testosterone propionate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Testosterone	Pralatrexate may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Tetracaine.
Tetracycline	Tetracycline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tetradecyl	Pralatrexate may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Pralatrexate.
Thiabendazole	Thiabendazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Thiethylperazine	Thiethylperazine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Thiotepa	The risk or severity of adverse effects can be increased when Thiotepa is combined with Pralatrexate.
Tiaprofenic acid	Tiaprofenic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tick- encephalitis	The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Pralatrexate.
Ticlopidine	Ticlopidine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tiludronic acid	Tiludronic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Timolol	Timolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tinidazole	Tinidazole may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Pralatrexate.
Tiopronin	Pralatrexate may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Tiotropium	Tiotropium may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tirofiban	Tirofiban may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tivozanib	Tivozanib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tixocortol	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Tixocortol.

Tobramycin	Pralatrexate may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tocilizumab	The risk or severity of adverse effects can be increased when Tocilizumab is combined with Pralatrexate.
Tocopherol	Pralatrexate may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tofacitinib	Pralatrexate may increase the immunosuppressive activities of Tofacitinib.
Tolazamide	Tolazamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tolbutamide	Tolbutamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tolcapone	Tolcapone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tolfenamic acid	Tolfenamic acid may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tolmetin	Tolmetin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tolterodine	Tolterodine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tolvaptan	Tolvaptan may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Topiramate	Topiramate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Pralatrexate.
Torasemide	Torasemide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Pralatrexate.
Trabectedin	The risk or severity of adverse effects can be increased when Trabectedin is combined with Pralatrexate.
Tramadol	Tramadol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Trametinib	Pralatrexate may decrease the excretion rate of Trametinib which could result in a higher serum level.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Pralatrexate.
Trastuzumab	The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Pralatrexate.
Tretinoin	The risk or severity of adverse effects can be increased when Tretinoin is combined with Pralatrexate.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Pralatrexate.
Triamterene	Triamterene may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Triazolam	Triazolam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Trichlormethiazide	Trichlormethiazide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Triethylenetetram	Pralatrexate may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Pralatrexate.
Trilostane	The risk or severity of adverse effects can be increased when Trilostane is combined with Pralatrexate.
Trimebutine	Pralatrexate may decrease the excretion rate of Trimebutine which could result in a higher serum level.
Trimethoprim	Trimethoprim may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Trimetrexate	Trimetrexate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Tropisetron	Pralatrexate may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Pralatrexate.
Typhoid Vaccine	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Pralatrexate.
Typhoid Vi	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Pralatrexate.
Upadacitinib	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Upadacitinib.
Vaborbactam	Pralatrexate may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Valaciclovir	Valaciclovir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Valbenazine	Pralatrexate may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valdecoxib	Valdecoxib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Valganciclovir	Valganciclovir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Vancomycin	Pralatrexate may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Vandetanib	Vandetanib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Varenicline	Varenicline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Varicella zoster	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Pralatrexate.
Varicella zoster	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Pralatrexate.
Vedolizumab	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Vedolizumab.
Velpatasvir	Velpatasvir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Vemurafenib	Vemurafenib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Venetoclax	Venetoclax may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Venlafaxine	Venlafaxine may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.
Verapamil	Verapamil may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Vibrio antigen	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Pralatrexate.
Vilanterol	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Vilanterol.
Viloxazine	Pralatrexate may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Pralatrexate.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Pralatrexate.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Pralatrexate.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Pralatrexate.
Vismodegib	Vismodegib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Voclosporin	The risk or severity of adverse effects can be increased when Pralatrexate is combined with Voclosporin.
Vorinostat	The risk or severity of adverse effects can be increased when Vorinostat is combined with Pralatrexate.
Vortioxetine	Pralatrexate may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Voxilaprevir	Voxilaprevir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Warfarin	Pralatrexate may decrease the excretion rate of Warfarin which could result in a higher serum level.
Yellow fever vaccine	The risk or severity of infection can be increased when Yellow fever vaccine is combined with Pralatrexate.
Zaleplon	Zaleplon may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Zanamivir	Zanamivir may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Pralatrexate.
Zonisamide	Zonisamide may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.

Pregnancy and Lactation

FDA Pregnancy Category D

Pregnancy

FOLOTYN can cause fetal harm when administered to a pregnant woman. Pralatrexate was embryotoxic and fetotoxic in rats at IV doses of 0.06 mg/kg/day (0.36 mg/m2/day or about 1.2% of the clinical dose on an mg/m2 basis) given on gestation days 7 through 20. Treatment with pralatrexate caused a dose-dependent decrease in fetal viability manifested as an increase in late, early, and total resorptions. There was also a dose-dependent increase in post-implantation loss. In rabbits, IV doses of 0.03 mg/kg/day (0.36 mg/m2 /day) or greater given on
gestation days 8 through 21 also caused abortion and fetal lethality. This toxicity manifested as early and total resorptions, post-implantation loss, and a decrease in the total number of live fetuses. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Lactation

It is not known whether pralatrexate is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from this drug, a decision should be made whether to discontinue nursing or to discontinue FOLOTYN, taking into account the importance of FOLOTYN to the mother.

How should this medicine be used?

Pralatrexate injection comes as a solution (liquid) to be injected intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given over a period of 3 to 5 minutes once a week for 6 weeks as part of a 7-week cycle. Your treatment will probably continue until your condition worsens or you develop serious side effects.

Your doctor may need to adjust your dose, skip a dose, or stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with a pralatrexate injection.

You will need to take folic acid and vitamin B₁₂ during your treatment with pralatrexate injection to help prevent certain side effects. Your doctor will probably tell you to take folic acid by mouth every day beginning 10 days before you start your treatment and for 30 days after your final dose of pralatrexate injection. Your doctor will also probably tell you that you will need to receive a vitamin B₁₂ injection no more than 10 weeks before your first dose of pralatrexate injection and every 8 to 10 weeks for as long as your treatment continues.

What special precautions should I follow?

Before receiving a pralatrexate injection,

tell your doctor and pharmacist if you are allergic to pralatrexate injection, any other medications, or any of the ingredients in pralatrexate injection. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: aspirin and other nonsteroidal anti-inflammatory medications (NSAIDs) such as ibuprofen (Advil, Motrin) and naproxen (Aleve, Naprosyn); probenecid (Probalan), and trimethoprim/sulfamethoxazole (Bactrim). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
tell your doctor if you have or have ever had kidney or liver disease.
tell your doctor if you are pregnant, could be pregnant, or plan to become pregnant. You should not become pregnant while you are receiving pralatrexate injections. Talk to your doctor about birth control methods that you can use during your treatment. If you become pregnant while receiving a pralatrexate injection, call your doctor immediately. Pralatrexate injection may harm the fetus.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving a pralatrexate injection.

References

https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022468lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022468s012lbl.pdf
https://www.drugs.com/history/folotyn.html
https://www.cancer.gov/about-cancer/treatment/drugs/pralatrexate
https://pubchem.ncbi.nlm.nih.gov/compound/Pralatrexate
https://pubchem.ncbi.nlm.nih.gov/compound/Pralatrexate
https://go.drugbank.com/drugs/DB06813
https://www.drugs.com/mtm/pralatrexate.html
https://medlineplus.gov/druginfo/meds/a610001.html
https://en.wikipedia.org/wiki/Pralatrexate
https://www.mayoclinic.org/drugs-supplements/pralatrexate-intravenous-route/side-effects/drg-20073415?p=1
https://www.webmd.com/drugs/2/drug-153046/pralatrexate-intravenous/details/list-contraindications
CAS Common Chemistry

https://creativecommons.org/licenses/by-nc/4.0/

Pralatrexate

https://commonchemistry.cas.org/detail?cas_rn=146464-95-1
ChemIDplus

LICENSE

https://www.nlm.nih.gov/copyright.html

Pralatrexate [USAN:INN]

https://chem.nlm.nih.gov/chemidplus/sid/0146464951

https://chem.nlm.nih.gov/chemidplus/
DrugBank

https://www.drugbank.ca/legal/terms_of_use

Pralatrexate

https://www.drugbank.ca/drugs/DB06813
DTP/NCI

https://www.cancer.gov/policies/copyright-reuse

Pralatrexate

https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=754230
EPA DSSTox

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

Pralatrexate

https://comptox.epa.gov/dashboard/DTXSID3048578

https://comptox.epa.gov/dashboard/chemical-lists/
European Chemicals Agency (ECHA)

https://echa.europa.eu/web/guest/legal-notice

https://echa.europa.eu/information-on-chemicals

https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/210739
FDA Global Substance Registration System (GSRS)

https://www.fda.gov/about-fda/about-website/website-policies#linking

PRALATREXATE

https://gsrs.ncats.nih.gov/ginas/app/beta/substances/A8Q8I19Q20
Hazardous Substances Data Bank (HSDB)

Pralatrexate

https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7786
ChEBI

Pralatrexate

http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:71223

ChEBI Ontology

http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
FDA Pharm Classes

https://www.fda.gov/about-fda/about-website/website-policies#linking

PRALATREXATE

https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm

FDA Pharmacological Classification

https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
LiverTox

LICENSE

https://www.nlm.nih.gov/copyright.html

Pralatrexate

https://www.ncbi.nlm.nih.gov/books/n/livertox/Pralatrexate/
NCI Thesaurus (NCIt)

https://www.cancer.gov/policies/copyright-reuse

https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2250

NCI Thesaurus Tree

https://ncit.nci.nih.gov
ChEMBL

http://www.ebi.ac.uk/Information/termsofuse.html

https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201746/

ChEMBL Protein Target Tree

https://www.ebi.ac.uk/chembl/g/#browse/targets
Comparative Toxicogenomics Database (CTD)

http://ctdbase.org/about/legal.jsp

10-propargyl-10-deazaaminopterin

https://ctdbase.org/detail.go?type=chem&acc=C418863
Drug Gene Interaction database (DGIdb)

http://www.dgidb.org/downloads

PRALATREXATE

https://www.dgidb.org/drugs/PRALATREXATE
IUPHAR/BPS Guide to PHARMACOLOGY

https://www.guidetopharmacology.org/about.jsp#license

pralatrexate

https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6840

Guide to Pharmacology Target Classification

https://www.guidetopharmacology.org/targets.jsp
Therapeutic Target Database (TTD)

Pralatrexate

http://idrblab.net/ttd/data/drug/details/D02LWU
ClinicalTrials.gov

https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use

https://clinicaltrials.gov/
DailyMed

LICENSE

https://www.nlm.nih.gov/copyright.html

PRALATREXATE

https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=PRALATREXATE
Drug Induced Liver Injury Rank (DILIrank) Dataset

https://www.fda.gov/about-fda/about-website/website-policies#linking

pralatrexate

https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset
European Medicines Agency (EMA)

https://www.ema.europa.eu/en/about-us/legal-notice

Folotyn (EMEA/H/C/002096)

https://www.ema.europa.eu/en/medicines/human/EPAR/folotyn
EU Clinical Trials Register

https://www.clinicaltrialsregister.eu/
FDA Orange Book

https://www.fda.gov/about-fda/about-website/website-policies#linking

https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
WHO Anatomical Therapeutic Chemical (ATC) Classification

https://www.whocc.no/copyright_disclaimer/

https://www.whocc.no/atc/

ATC Code

https://www.whocc.no/atc_ddd_index/
National Drug Code (NDC) Directory

https://www.fda.gov/about-fda/about-website/website-policies#linking

PRALATREXATE

https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
MassBank of North America (MoNA)

https://mona.fiehnlab.ucdavis.edu/documentation/license

Pralatrexate(Folotyn)

https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22OGSBUKJUDHAQEA-WMCAAGNKSA-N%22%27
NCI Cancer Drugs

LICENSE

https://www.cancer.gov/policies/copyright-reuse

Folotyn (Pralatrexate)

https://www.cancer.gov/about-cancer/treatment/drugs/pralatrexate
NLM RxNorm Terminology

https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html

pralatrexate

https://rxnav.nlm.nih.gov/id/rxnorm/662019
PubChem

https://pubchem.ncbi.nlm.nih.gov
Thieme Chemistry

https://creativecommons.org/licenses/by-nc-nd/4.0/

https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=35052338-593811014
Wikidata

https://creativecommons.org/publicdomain/zero/1.0/

Pralatrexate

https://www.wikidata.org/wiki/Q637059
Medical Subject Headings (MeSH)

https://www.nlm.nih.gov/copyright.html

10-propargyl-10-deazaaminopterin

https://www.ncbi.nlm.nih.gov/mesh/67418863

MeSH Tree

http://www.nlm.nih.gov/mesh/meshhome.html
KEGG

https://www.kegg.jp/kegg/legal.html

Therapeutic category of drugs in Japan

http://www.genome.jp/kegg-bin/get_htext?br08301.keg

Anatomical Therapeutic Chemical (ATC) classification

http://www.genome.jp/kegg-bin/get_htext?br08303.keg

Target-based classification of drugs

http://www.genome.jp/kegg-bin/get_htext?br08310.keg

Drug Groups

http://www.genome.jp/kegg-bin/get_htext?br08330.keg

Drug Classes

http://www.genome.jp/kegg-bin/get_htext?br08332.keg
UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

GHS Classification Tree

http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
PATENTSCOPE (WIPO)

SID 390746020

https://pubchem.ncbi.nlm.nih.gov/substance/390746020
NCBI

https://www.ncbi.nlm.nih.gov/projects/linkout

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

Write when the problem started and how it changed.
Bring old prescriptions, investigation reports, and current medicines.
Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

What is the most likely cause of my symptoms?
Which danger signs mean I should go to hospital quickly?
Which tests are necessary now, and which can wait?
How should I take medicines safely and what side effects should I watch for?
When should I come for follow-up?

Tests to discuss

Vital signs: temperature, pulse, blood pressure, oxygen saturation
Basic physical examination by a clinician
CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

Avoid heavy lifting, sudden bending, and prolonged bed rest.
Use comfortable posture and gentle movement as tolerated.
Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

Do not start antibiotics without a proper medical decision.
Do not use steroid tablets or injections casually for quick relief.
Do not delay emergency care because of home remedies.

Get urgent help if

Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.

Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician

Tests to discuss with doctor

Neurological examination for leg power, sensation, reflexes, and straight leg raise
X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms

Questions to ask

What is the most likely cause of my symptoms?
Which warning signs mean I should go to emergency care?
Which tests are really needed now?
Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Go to emergency care if you notice:

Severe or rapidly worsening symptoms
Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration

Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.

Step 1
Check danger signs first

If danger signs are present, seek emergency care and do not wait for online information.
Step 2
Record the symptom story

Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.
Step 3
Visit a qualified clinician

A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.
Step 4
Do only useful tests

Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.
Step 5
Follow up and return early if worse

If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips

Take a written symptom diary and all previous prescriptions/test reports.
Do not hide medicines already taken, even herbal or over-the-counter medicines.
Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

Read, save, and share this guide

Article Summary

Key Takeaways

RX Patient Tools

Mechanism of Action

Indications

How should this medicine be used?

What special precautions should I follow?

Before receiving a pralatrexate injection,

Explore this medical topic

Related medical topics

Continue through a complete learning pathway

Conditions & Diseases

Tests & Investigations

Medicines

Cancer Knowledge